GSK Bets on Chimp Virus with $321 Million Vaccines Buy

29.05.2013 - GlaxoSmithKline is betting on a new vaccine technology based on chimpanzee viruses by acquiring Swiss-based Okairos for €250 million ($321 million) - the latest bolt-on biotech buy...